Molecule Information
      General Information of the Molecule (ID: Mol00046)
  
  | Name | Ceramide synthase 2 (CERS2)
                                ,Homo sapiens
                               | ||||
|---|---|---|---|---|---|
| Synonyms | CerS2; LAG1 longevity assurance homolog 2; SP260; Sphingosine N-acyltransferase CERS2; Tumor metastasis-suppressor gene 1 protein; Very-long-chain ceramide synthase CERS2; LASS2; TMSG1     Click to Show/Hide | ||||
| Molecule Type | Protein | ||||
| Gene Name | CERS2 | ||||
| Gene ID | |||||
| Location | chr1:150960583-150975003[-] | ||||
| Sequence | MLQTLYDYFWWERLWLPVNLTWADLEDRDGRVYAKASDLYITLPLALLFLIVRYFFELYV ATPLAALLNIKEKTRLRAPPNATLEHFYLTSGKQPKQVEVELLSRQSGLSGRQVERWFRR RRNQDRPSLLKKFREASWRFTFYLIAFIAGMAVIVDKPWFYDMKKVWEGYPIQSTIPSQY WYYMIELSFYWSLLFSIASDVKRKDFKEQIIHHVATIILISFSWFANYIRAGTLIMALHD SSDYLLESAKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWILHCTLVYPLELYPAFF GYYFFNSMMGVLQLLHIFWAYLILRMAHKFITGKLVEDERSDREETESSEGEEAAAGGGA KSRPLANGHPILNNNHRKND     Click to Show/Hide | ||||
| Function | Ceramide synthase that catalyzes the transfer of the acyl chain from acyl-CoA to a sphingoid base, with high selectivity toward very-long-chain fatty acyl-CoA (chain length C22-C27). N-acylates sphinganine and sphingosine bases to form dihydroceramides and ceramides in de novo synthesis and salvage pathways, respectively. Plays a non-redundant role in the synthesis of ceramides with very-long-chain fatty acids in kidney, liver and brain. Regulates the abundance of myelin-specific sphingolipids galactosylceramide and sulfatide that affects myelin sheath architecture and motor neuron functions.     Click to Show/Hide | ||||
| Uniprot ID | |||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
      Type(s) of Resistant Mechanism of This Molecule
  
  
      Drug Resistance Data Categorized by Drug
  
  Approved Drug(s)
      2 drug(s) in total
      
    | Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|  | ||||
| Disease Class: Bladder cancer | [1] | |||
| Resistant Disease | Bladder cancer [ICD-11: 2C94.0] | |||
| Resistant Drug | Cisplatin | |||
| Molecule Alteration | Expression | Down-regulation | ||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Activation | hsa05200 | ||
| Drp1 signaling pathway | Activation | hsa04668 | ||
| In Vitro Model | 5637 cells | Bladder | Homo sapiens (Human) | CVCL_0126 | 
| J82 cells | Bladder | Homo sapiens (Human) | CVCL_0359 | |
| RT4 cells | Bladder | Homo sapiens (Human) | CVCL_0036 | |
| SV-HUC-1 cells | Bladder | Homo sapiens (Human) | CVCL_3798 | |
| T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
| Experiment for Molecule Alteration | Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance | CCK8 assay; Colony formation assay; Flow cytometry assay | |||
| Mechanism Description | microRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells through Drp1 signaling. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|  | ||||
| Disease Class: Bladder cancer | [1] | |||
| Resistant Disease | Bladder cancer [ICD-11: 2C94.0] | |||
| Resistant Drug | Doxorubicin | |||
| Molecule Alteration | Expression | Down-regulation | ||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Activation | hsa05200 | ||
| Drp1 signaling pathway | Activation | hsa04668 | ||
| In Vitro Model | 5637 cells | Bladder | Homo sapiens (Human) | CVCL_0126 | 
| J82 cells | Bladder | Homo sapiens (Human) | CVCL_0359 | |
| RT4 cells | Bladder | Homo sapiens (Human) | CVCL_0036 | |
| SV-HUC-1 cells | Bladder | Homo sapiens (Human) | CVCL_3798 | |
| T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
| Experiment for Molecule Alteration | Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance | CCK8 assay; Colony formation assay; Flow cytometry assay | |||
| Mechanism Description | microRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells through Drp1 signaling. | |||
      Disease- and Tissue-specific Abundances of This Molecule
  
  
      ICD Disease Classification 02
       
    
    
  | Differential expression of molecule in resistant diseases | ||
| The Studied Tissue | Bladder tissue | |
| The Specified Disease | Bladder cancer | |
| The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 6.37E-05; Fold-change: 3.31E-01; Z-score: 2.02E+00 | |
| Molecule expression in the diseased tissue of patients Molecule expression in the normal tissue of healthy individuals | ||
| Disease-specific Molecule Abundances |   | Click to View the Clearer Original Diagram | 
      
      Tissue-specific Molecule Abundances in Healthy Individuals
       
    
    
  |   | ||
      References
  
  visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
